An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

Alan Sandler, Vera Hirsh, Martin Reck, Joachim von Pawel, Wallace Akerley, David H. Johnson

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis. Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on angiogenesis for growth and metastasis. Anti-VEGF therapy has demonstrated clinical benefits in the first-line treatment of NSCLC. Central nervous system (CNS) metastases are a common occurrence among patients with lung cancer and confer significant morbidity and mortality. The risk of CNS hemorrhage in NSCLC patients receiving anti-VEGF therapy is still relatively unexplored because patients with CNS metastases have generally been excluded from trials of anti-VEGF therapy due to a perceived increased risk of cerebral hemorrhage. Recently, large prospective, randomized trials, open-label studies and observational cohort studies in NSCLC have provided data on the incidence of CNS hemorrhage in large patient populations, reflective of community practice. Methods: We conducted a literature review for the available data on the incidence of CNS hemorrhage in NSCLC patients with brain metastases receiving anti-VEGF therapy. Results: There is no significantly increased risk of CNS hemorrhage in patients with NSCLC and emerging (previously untreated) or pretreated CNS metastases receiving anti-VEGF therapy. Conclusions: We conclude that clinical trial data indicate that anti-VEGF therapy can be considered for NSCLC patients with emerging or pretreated CNS metastases.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalLung Cancer
Volume78
Issue number1
DOIs
StatePublished - Oct 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Vascular Endothelial Growth Factor A
Central Nervous System
Hemorrhage
Neoplasm Metastasis
Incidence
Brain
Therapeutics
Cerebral Hemorrhage
Observational Studies
Lung Neoplasms
Cohort Studies
Clinical Trials
Morbidity
Mortality
Growth
Population
Neoplasms

Keywords

  • Anti-VEGF therapy
  • Bevacizumab
  • Brain metastases
  • CNS hemorrhage
  • CNS metastases
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. / Sandler, Alan; Hirsh, Vera; Reck, Martin; von Pawel, Joachim; Akerley, Wallace; Johnson, David H.

In: Lung Cancer, Vol. 78, No. 1, 10.2012, p. 1-7.

Research output: Contribution to journalArticle

Sandler, Alan ; Hirsh, Vera ; Reck, Martin ; von Pawel, Joachim ; Akerley, Wallace ; Johnson, David H. / An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. In: Lung Cancer. 2012 ; Vol. 78, No. 1. pp. 1-7.
@article{b39c085d107345f4b345709242a7ffef,
title = "An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases",
abstract = "Background: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis. Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on angiogenesis for growth and metastasis. Anti-VEGF therapy has demonstrated clinical benefits in the first-line treatment of NSCLC. Central nervous system (CNS) metastases are a common occurrence among patients with lung cancer and confer significant morbidity and mortality. The risk of CNS hemorrhage in NSCLC patients receiving anti-VEGF therapy is still relatively unexplored because patients with CNS metastases have generally been excluded from trials of anti-VEGF therapy due to a perceived increased risk of cerebral hemorrhage. Recently, large prospective, randomized trials, open-label studies and observational cohort studies in NSCLC have provided data on the incidence of CNS hemorrhage in large patient populations, reflective of community practice. Methods: We conducted a literature review for the available data on the incidence of CNS hemorrhage in NSCLC patients with brain metastases receiving anti-VEGF therapy. Results: There is no significantly increased risk of CNS hemorrhage in patients with NSCLC and emerging (previously untreated) or pretreated CNS metastases receiving anti-VEGF therapy. Conclusions: We conclude that clinical trial data indicate that anti-VEGF therapy can be considered for NSCLC patients with emerging or pretreated CNS metastases.",
keywords = "Anti-VEGF therapy, Bevacizumab, Brain metastases, CNS hemorrhage, CNS metastases, NSCLC",
author = "Alan Sandler and Vera Hirsh and Martin Reck and {von Pawel}, Joachim and Wallace Akerley and Johnson, {David H.}",
year = "2012",
month = "10",
doi = "10.1016/j.lungcan.2012.07.004",
language = "English (US)",
volume = "78",
pages = "1--7",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

AU - Sandler, Alan

AU - Hirsh, Vera

AU - Reck, Martin

AU - von Pawel, Joachim

AU - Akerley, Wallace

AU - Johnson, David H.

PY - 2012/10

Y1 - 2012/10

N2 - Background: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis. Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on angiogenesis for growth and metastasis. Anti-VEGF therapy has demonstrated clinical benefits in the first-line treatment of NSCLC. Central nervous system (CNS) metastases are a common occurrence among patients with lung cancer and confer significant morbidity and mortality. The risk of CNS hemorrhage in NSCLC patients receiving anti-VEGF therapy is still relatively unexplored because patients with CNS metastases have generally been excluded from trials of anti-VEGF therapy due to a perceived increased risk of cerebral hemorrhage. Recently, large prospective, randomized trials, open-label studies and observational cohort studies in NSCLC have provided data on the incidence of CNS hemorrhage in large patient populations, reflective of community practice. Methods: We conducted a literature review for the available data on the incidence of CNS hemorrhage in NSCLC patients with brain metastases receiving anti-VEGF therapy. Results: There is no significantly increased risk of CNS hemorrhage in patients with NSCLC and emerging (previously untreated) or pretreated CNS metastases receiving anti-VEGF therapy. Conclusions: We conclude that clinical trial data indicate that anti-VEGF therapy can be considered for NSCLC patients with emerging or pretreated CNS metastases.

AB - Background: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis. Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on angiogenesis for growth and metastasis. Anti-VEGF therapy has demonstrated clinical benefits in the first-line treatment of NSCLC. Central nervous system (CNS) metastases are a common occurrence among patients with lung cancer and confer significant morbidity and mortality. The risk of CNS hemorrhage in NSCLC patients receiving anti-VEGF therapy is still relatively unexplored because patients with CNS metastases have generally been excluded from trials of anti-VEGF therapy due to a perceived increased risk of cerebral hemorrhage. Recently, large prospective, randomized trials, open-label studies and observational cohort studies in NSCLC have provided data on the incidence of CNS hemorrhage in large patient populations, reflective of community practice. Methods: We conducted a literature review for the available data on the incidence of CNS hemorrhage in NSCLC patients with brain metastases receiving anti-VEGF therapy. Results: There is no significantly increased risk of CNS hemorrhage in patients with NSCLC and emerging (previously untreated) or pretreated CNS metastases receiving anti-VEGF therapy. Conclusions: We conclude that clinical trial data indicate that anti-VEGF therapy can be considered for NSCLC patients with emerging or pretreated CNS metastases.

KW - Anti-VEGF therapy

KW - Bevacizumab

KW - Brain metastases

KW - CNS hemorrhage

KW - CNS metastases

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84866144231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866144231&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2012.07.004

DO - 10.1016/j.lungcan.2012.07.004

M3 - Article

C2 - 22877947

AN - SCOPUS:84866144231

VL - 78

SP - 1

EP - 7

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -